Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 2/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15705197 | 0.87 | ALDH1A1 (0.30) | USP2ALDH1A1MAPTHPGDHTT | |
| SCHEMBL5952180 | 0.81 | KMT2A (0.42) | ALDH1A1MAPTHSD17B10KDM4E | |
| SCHEMBL20524643 | 0.81 | HCAR2 (0.46) | HCAR2NOTUMKDM5AKDM5BKDM4E | |
| SCHEMBL22637318 | 0.79 | NOTUM (0.34) | HCAR2NOTUMKDM5AKDM5BTDP1 | |
| SCHEMBL5952390 | 0.77 | CNR2 (0.39) | ALDH1A1KDM4E | |
| SCHEMBL553835 | 0.77 | GABRP (0.44) | HSD17B10HCAR2NOTUMKDM5AKDM5B | |
| SCHEMBL5951752 | 0.74 | HCAR2 (0.37) | ALDH1A1HTTHCAR2NOTUMKDM5A | |
| SCHEMBL971141 | 0.74 | HCAR2 (0.42) | HCAR2NOTUMKDM5AKDM5BKDM4E | |
| SCHEMBL26111310 | 0.73 | KDM5A (0.31) | NOTUMKDM5AKDM5B | |
| SCHEMBL20268740 | 0.73 | NOTUM (0.33) | ALDH1A1HTTHCAR2NOTUMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | USP2 4085/4885ALDH1A1 1389/4885MAPT 3479/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | USP2 4375/4885ALDH1A1 862/4885MAPT 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.